IRP News

Dr. Thorsten Kahnt Wins 2022 AChemS Young Investigator Award for Research in Olfaction or Nasal Chemosensation

The Association for Chemoreception Sciences has awarded Dr. Thorsten Kahnt with it’s Young Investigator Award for Research in Olfaction or Nasal Chemosensation. Dr. Kahnt is the newest Principal Investigator at the NIDA IRP and he will be leading the Learning and Decision-Making Unit. Congratulations, Dr. Kahnt! Acknowledgements from Dr. Kahnt I am very grateful to the… [Read More]

More IRP News

Hot Off the Press

Reversing anterior insular cortex neuronal hypoexcitability attenuates compulsive behavior in adolescent rats

Hot Off the Press – May 27, 2022 Published in Proceedings of the National Academy of Sciences (PNAS) by Dr. Kshitij Jadhav (2019 Predoctoral trainee at NIDA-IRP), Dr. Benjamin Boutrel (Ph.D. supervisor, University of Lausanne, Switzerland) and Dr. Carl Lupica (Project Supervisor, Electrophysiology Research Section, NIDA-IRP). Summary Adolescents are labelled as high risk-taking impulsive individuals… [Read More]

More Hot Off the Press

Reviews To Read

Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models

Reviews To Read – February 2022. Published in Lancet Gastroenterology and Hepatology and Coauthored by Lorenzo Leggio of the NIDA IRP Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section. Despite its increased recognition as a major public health issue, alcohol use disorder is mostly underdiagnosed and undertreated. The undertreatment and underdiagnosis of alcohol use disorder is most concerning… [Read More]

More Reviews to Read

Featured Papers

Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search

Featured Paper of the Month – September 2022 Published in Molecular Psychiatry by Jordi Bonaventura and Michael Michaelides, et al. of the NIDA IRP Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit. Summary The use of racemic ketamine and the FDA approval of (S)-ketamine are promising developments for the treatment of depression. Nevertheless, racemic ketamine and (S)-ketamine… [Read More]

More Featured Papers